[关键词]
[摘要]
遗传性视网膜病是一组由基因异常引起的进行性致盲性疾病,具有高度遗传和临床异质性。随着致病基因谱不断扩展、递送载体持续优化及临床转化研究快速推进,基因治疗已成为该领域最具前景的精准干预技术。近年来,以腺相关病毒为核心的基因替代治疗率先取得突破,voretigene neparvovec(Luxturna)的临床应用标志着视网膜基因治疗正式进入临床阶段。与此同时,基因编辑、突变非依赖性治疗(包括光遗传学)等技术不断发展,为显性遗传病、大片段基因缺失/重复变异相关疾病及终末期患者提供了新的干预思路。当前,视网膜基因治疗虽已取得重要进展,但仍面临载体容量受限、免疫反应、给药路径优化、治疗窗口判定及成本可及性不足等问题。文章就遗传性视网膜病基因治疗的主要技术、递送系统优化、代表性疾病临床进展及现阶段挑战进行综述,并对未来发展方向进行展望。
[Key word]
[Abstract]
Inherited retinal diseases are a group of progressive blinding disorders caused by genetic defects, characterized by marked genotypic and phenotypic heterogeneity. With the continuous expansion of disease-causing gene spectra, improvements in vector engineering, and rapid progress in translational studies, gene therapy has emerged as one of the most promising precision treatment strategies for these conditions. In recent years, adeno-associated virus(AAV)-based gene augmentation therapy has achieved the most significant clinical progress, and the approval of voretigene neparvovec(Luxturna)represents a landmark in retinal gene therapy. Meanwhile, gene editing and mutation-independent approaches, including optogenetic therapy are providing new options for dominant inherited disorders, diseases caused by large gene deletions or duplications, and patients at advanced stages. Despite these advances, several barriers continue to hinder broader clinical application, including limited vector capacity, immune responses, the need to optimize delivery routes, challenges in identifying therapeutic windows, and limited cost accessibility. This article reviews the primary technologies for gene therapy of inherited retinal diseases, optimization of delivery systems, clinical progress in representative diseases, and current challenges, and provides a perspective on future development directions.
[中图分类号]
[基金项目]
2024年湖南省自然科学基金项目(No.2024JJ9018)